Acelot to Present New ALS Therapy Data in Clearwater
The company will share preclinical findings on a potential treatment for sporadic ALS at the 2026 NEALS meeting.
Updated on Oct. 26, 2026 in Alzheimer’s
Acelot researchers are set to present new preclinical findings on a potential treatment for sporadic ALS at the 2026 NEALS meeting in Clearwater, Florida. The event, which runs from October 27 to October 30, 2026, will feature discussions on emerging therapeutic targets.
Why it matters
Understanding new developments in targeting aggregated proteins is essential for patients and families tracking the progress of experimental ALS therapies. Acelot is testing a new approach designed to address the underlying cellular mechanisms of the disease.
Acelot will debut preclinical data from its TDP-43 drug program at the NEALS meeting. This research remains in early development, with future outcomes for patients yet to be established.
The players
Acelot
A South San Francisco-based biotech company focused on using artificial intelligence for drug discovery.
Mark Forman
The Chief Medical Officer at Acelot who leads the company's research into TDP-43-targeted therapies.
Katie Planey
The CEO of Acelot who participates in industry-wide discussions regarding new therapeutic targets.
The details
Acelot utilizes the RESOLUTE AI computational chemistry platform, which integrates physics-based and AI modeling to design small molecules. These molecules are developed to target aggregated TDP-43, a protein implicated in the progression of sporadic ALS. By specifically focusing on these aggregates, the company aims to modify the underlying disease process.
Timeline
• The 2026 NEALS meeting runs from October 27 to October 30, 2026.
• CEO Katie Planey joins an industry roundtable on October 28, 2026, at 3:30 PM ET.
• CMO Mark Forman presents preclinical data on October 30, 2026, at 11:40 AM ET.
Health Landscape
The development of these small molecules reflects the broader transition in neurodegenerative research toward precision targeting of aggregated proteins. This approach seeks to provide alternatives to traditional therapeutic pathways for sporadic ALS.
These findings are strictly preclinical and do not represent a currently available treatment option for patients. Readers should discuss any questions about clinical trial eligibility or new treatment developments with their neurologist.
The takeaway
Acelot is testing a new computational approach to targeting protein aggregation in ALS. Patients and caregivers should continue to monitor updates from neurological specialists regarding when or if such therapies reach clinical trial stages.
Further reading
Learn more about ongoing research into Alzheimer’s and related neurodegenerative conditions.
Source note: This article includes information reported by Firstwordpharma.
